nephromag 0.2 mg/2.5 ml
rotop pharmaka gmbh - mertiatid - preparasjonssett til radioaktive legemidler - 0.2 mg/2.5 ml
octreoscan 111 mbq/ ml / 10 mikrog
curium netherlands b.v. - indium (111in) klorid / pentetreotid - preparasjonssett til radioaktive legemidler - 111 mbq/ ml / 10 mikrog
stabilised ceretec -
ge healthcare as - kobolt(ii)kloridheksahydrat / eksametazim - preparasjonssett til radioaktive legemidler
sodium iodide [131i] injection ge healthcare 925 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 925 mbq/ ml
sodium iodide [131i] injection ge healthcare 74 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 74 mbq/ ml
technescan lyomaa -
curium netherlands b.v. - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, oppløsning
technescan pyp 20 mg
curium netherlands b.v. - natriumpyrofosfat - preparasjonssett til radioaktive legemidler - 20 mg
venticoll 0.5 mg
ge healthcare as - albumin, humant, kolloidale partikler - pulver til inhalasjonsvæske til nebulisator, oppløsning - 0.5 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
activyl
intervet international bv - indoxacarb - ectoparasiticides for utvortes bruk, inkl. insektmidler, indoxacarb - dogs; cats - behandling og forebygging av loppeangrep. for hunder og katter: behandling og forebygging av loppeangrep. veterinærpreparatet kan brukes som en del av en behandlingsstrategi for loppe-allergi dermatitt. utvikle stadier av lopper i kjæledyrets umiddelbare omgivelser blir drept etter kontakt med activyl-behandlede kjæledyr.